Recormon (Epoetin Beta)1. Key BenefitsRecormon is a medicine that stimulates red-blood-cell growth, with epoetin beta as a copy of the human hormone erythropoietin. Clinical studies show hemoglobin levels rose significantly from 77.15 ± 2.32 g/l before treatment to 110.71 ± 6.25 g/l at the end of month three. The medication provides consistent erythropoietic response, improving energy levels and quality of life while reducing transfusion requirements. Neo-Recormon had a considerable positive effect on the overall condition of patients.2. IndicationsRecormon is indicated for multiple clinical scenarios:Treatment of anemia in people with chronic kidney disease (CKD), whether they’re on dialysis or notTreatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysisPrevention or treatment of anemia caused by surgery or other medications, such as those for HIV or cancerCancer-associated anemia in specific patient populationsPre-operative autologous blood collection programs3. How it WorksErythropoietin is a recombinant form of human erythropoietin used to increase differentiation of progenitor cells to red blood cells in the treatment of anemia. Erythropoietin is produced by the kidneys and stimulates the production of red blood cells. Epoetin beta binds to erythropoietin receptors on bone marrow progenitor cells, stimulating their proliferation and differentiation into mature red blood cells, thereby increasing hemoglobin levels and oxygen-carrying capacity.4. Quality and SafetyManufacturing Excellence: Recormon is produced by Roche using advanced recombinant DNA technology, ensuring consistent potency and pharmaceutical quality.Safety Profile: As anaphylactoid reactions were observed in isolated cases, it is recommended that the first dose be administered under medical supervision. The side effects for Recormon are usually mild and generally well tolerated. No significant changes were found in the rate of progression of renal failure nor were there any marked side effects and intolerability to the drug observed.Venous Thromboembolism Risk: Studies have shown venous thromboembolism and mortality associated with recombinant erythropoietin administration for cancer-associated anemia.5. Important ConsiderationsContraindications:Known hypersensitivity to the active substance or any of the excipientsPoorly controlled hypertensionIn autologous blood programs, contraindicated in patients who, in the month preceding treatment, cannot donate bloodSpecial Precautions:Should be used with extreme caution in patients with blood clotting disorders since the risks of severe adverse effects are very highAny disease of the heart and blood vessels should be reported to the doctor before treatmentIf given in high doses (more than 4000 IU/kg), epoetin-beta can cause rapid increase of the hematologic parametersAdministration Guidelines:Can be administered under the skin or into the veinsTypically given once to three times a weekThe pre-filled syringe is ready for use and is for single use onlyTherapy should be initiated by physicians experienced in the indicated conditionsMonitoring Requirements:Regular hemoglobin and hematocrit monitoringBlood pressure surveillance throughout treatmentIron status evaluation to ensure adequate iron storesAssessment for thrombotic eventsProfessional Note: Substitution by any other biological medicinal product requires the consent of the prescribing physician. Healthcare providers must carefully monitor patients for efficacy and safety parameters, particularly in cancer patients where thrombotic risk may be elevated.ReferencesEpoetin-beta (Recormon-Roche) in the treatment of renal anemia in patients with chronic renal failure. PubMed, 2001Epoetin beta (Recormon) | HemOnc.org – A Hematology Oncology WikiRecormon® (Epoetin Beta) in Pre-Filled Syringe – Thog Pharmacy Co.Recormon: Dosages and Ingredients | Full Prescribing Info | MIMS PhilippinesErythropoetin-beta (Recormon) – HealthHub SingaporeRoche | Recormon (epoetin beta) – Official Manufacturer InformationErythropoietin: Uses, Interactions, Mechanism of Action | DrugBank Online
